Skyepharma has initiated Phase III clinical trials of the oral controlled release formulation of GlaxoSmithKline‘s Requip (Ropinirole HCl). The new once daily formulation for Parkinson’s disease has been developed utilizing SkyePharma’s Geomatrix technology.
Requip OCR is expected to simplify the treatment regime for patients using this drug, thus improving patient convenience and compliance.
The company described the move as a significant milestone.